TAZ has emerged as a key player in organ growth and tumorigenesis. We combined in vitro, in vivo, and in situ analyses to define the role of TAZ in human lung cancer.
Introduction
Lung cancer is the leading cause of cancer death worldwide. Despite the high histological heterogeneity, the overall prognosis for lung cancer is extremely poor, with non-small cell lung cancer (NSCLC) representing 85% of all diagnosed cases (1) .
Through the thorough characterization of human cancer tissues, distinct molecular aberrations have been identified in small subgroups of patients and are now being successfully exploited for therapeutic intervention, including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase, and c-ros oncogene 1 fusion proteins (2, 3) . However, for the vast majority of patients, treatment options are scant and the overall prognosis remains poor, emphasizing the need to uncover additional molecular mechanisms important in lung cancer tumorigenesis.
The transcriptional coactivator with PDZ-binding motif (TAZ), also known as WW-domain containing transcription regulator-1 (WWTR1), was originally identified as a 14-3-3 interacting protein (4) . The regulation of TAZ and its paralog, Yes-associated protein (YAP), occurs primarily via the Hippo pathway, which is conserved from flies to humans (5) . TAZ acts mainly through the TEAD family of transcription factors to stimulate expression of genes that promote cell proliferation and control organ size (6) . TAZ has also been suggested to be involved in other biological processes, including mesenchymal stem cell differentiation via modulation of Runx2-To investigate the physiological role of TAZ, we previously analyzed TAZ knockout mice (11) . TAZ deficiency caused abnormal alveolarization during lung development, leading to enlarged airspaces with low elastance. Taz-heterozygous mice were more resistant to bleomycin-induced lung fibrosis. We identified connective tissue growth factor (CTGF) as a downstream target of TAZ. TAZ has also been shown to interact with thyroid transcription factor-1 (TTF-1) (12) .
Despite its obvious role in lung morphogenesis and homeostasis under physiological conditions, recent studies showed that TAZ is overexpressed in various human cancers.
TAZ contributes to the tumorigenesis of breast cancer cells by promoting cell migration, invasion, anchorage-independent growth, and epithelial-mesenchymal transition (EMT) (13, 14) . In addition, TAZ confers cancer stem cell-related traits to breast cancer cells (15) , further highlighting its importance in tumor initiation and progression. TAZ also plays a role in malignant glioma, colorectal cancer, and papillary thyroid cancer cells (16) (17) (18) .
Few studies have analyzed the impact of TAZ in lung cancer, and these were restricted mainly to cell lines or included a limited number of NSCLC specimens (19) (20) (21) . The aim of our study was to analyze the role of TAZ in NSCLC using an integrative strategy, combining results from in vitro and in vivo analyses with molecular and clinical information of human lung cancer tissues.
Materials and Methods

Global gene expression and gene copy number analyses in human NSCLC tissues
The study population consisted of NSCLC patients surgically treated between 1995 (22) . The study was approved by the Uppsala Ethical Review Board (2006/325). RNA and DNA were isolated from 196 frozen tissue samples and used for microarray analysis as described previously (GEO accession GSE37745) (22) .
The meta-analysis was performed as described previously (22) and included nine publicly available Affymetrix expression data sets (the Uppsala cohort, GSE37745; GSE14814 (23); GSE3141 (24) ; GSE19188 (25) ; GSE4573 (26) ; GSE31210 (27) ; Shedden et al. 2008 (28) ; GSE29013 (29) ; GSE31547), together comprising 1,382 NSCLC patients and 22,277 probe sets overlapping the arrays.
Whole-genome SNP array experiments were performed according to standard protocols for Affymetrix Gene Chip Mapping 250K Nsp I arrays (Affymetrix, Santa Clara, CA, USA) on 192 of these cases, as described previously (30) . Copy number estimates for each SNP were calculated as the ratio of the sample chip effect in the Uppsala cohort and the robust average across 90 HapMap samples as the reference (31).
These non-log scale values were multiplied by two, and then CBS segmentation using default parameters was applied to the SNP-wise copy numbers (32) . TAZ copy number values were matched with the gene expression probe sets using the mean chromosomal position of the probe sets. Subsequently, the Spearman's rank correlation coefficient (rho) between TAZ gene expression and the copy number of the three probe sets was calculated.
Tissue microarray construction and immunohistochemistry
Research. A tissue microarray (TMA) encompassing 355 NSCLC cases was constructed as described previously (33) . Of these cases, 189 were also analyzed for global gene expression and gene copy number changes. Immunohistochemistry was performed according to standard procedures (33) . In brief, after antigen retrieval and blocking of endogenous peroxidase, slides were incubated with the anti-TAZ antibody (1:40 dilution, HPA007415, Sigma Aldrich, St. Louis, MO, USA) and the anti-amphiregulin antibody (1:10 dilution, AF262, R&D Systems, Minneapolis, MN, USA) for 30 min at room temperature (RT). After incubation with the secondary antibody (Dako REAL™ EnVision™, Dako, Glostrup, Denmark) for 30 min at RT, the staining was developed using diaminobenzidine solution for 10 min.
The immunostaining was evaluated under the supervision of a lung pathologist (PM).
The staining intensity was scored manually using a 4-grade scale: negative (0), weak (1), moderate (2), and strong (3). The fraction of stained tumor cells was scored as follows: no positive cells (0), 1-9% (1), 10-49% (2), 50-100% (3). For all stainings, one score was used per duplicate, representing the same tumor sample, on the arrays. The ordinal scores for the staining intensity and the fraction of stained tumor cells were multiplied, obtaining values in the range of 0-9. For survival analysis, the TAZ staining score was dichotomized at the median value of 6 (low: 0-6, high: 9).
Cell lines
The human lung cancer cell lines A549 and NCI-H441 (H441) were purchased from Cultures (Porton Down, UK). The 293FT cells were from Invitrogen (Carlsbad, CA, USA). All cell lines were cultured according to the manufacturer's protocols.
Small interfering RNA experiment
Small interfering RNAs (siRNA) against human TAZ (Stealth RNAi, si TAZ #1: HSS119545; si TAZ #2: HSS119546) and the negative control (Stealth RNAi, si NTC: #12935-300) were purchased from Invitrogen. A549 and H441 cells were transfected with 20 nM siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions.
Construction of the microRNA expression vectors
The microRNA (miRNA) expression vectors were constructed using the BLOCK-iT™ Pol II miR RNAi Expression Vector Kit with EmGFP (Invitrogen). Three pairs of sense and antisense oligonucleotides were designed for targeting TAZ (mi TAZ #1, #2, and #3; Supplementary Table S1) using BLOCK-iT™ RNAi Designer (http://rnaidesigner.Invitrogen.com/rnaiexpress/). The designed oligonucleotides were annealed, followed by ligation into the pcDNA6.2-GW/EmGFP-miR vector (Invitrogen). As the control, pcDNA6.2-GW/EmGFP-miR negative control plasmid (mi NTC; Invitrogen) was used. The sequence containing the miRNA coding region was transferred to the lentivirus vector CSII-EF-RfA via the Gateway cloning system (Invitrogen) according to the manufacturer's instructions.
Cloning of human TAZ cDNA
The open reading frame of TAZ, derived from the cDNA of A549 cells, was amplified by PCR using high-fidelity DNA polymerase (PrimeSTAR Max; Takara Bio, Shiga, Japan). The purified PCR fragment was subcloned into the lentiviral expression vector CSII-EF-RfA. The final insert was confirmed by DNA sequencing using the ABI PRISM® 310 Genetic Analyzer. A green fluorescent protein (GFP) expression vector was used as the control. 
Lentiviral infection
Immunoblot analysis
The detailed procedures for immunoblot analysis were described previously (34) . In brief, cells were lysed, followed by SDS gel electrophoresis and semi-dry transfer of the proteins to polyvinylidene difluoride membranes. They were probed with anti-TAZ (#2149; Cell Signaling, Beverly, MA, USA), anti-phospho-EGFR Y1068 (#3777; Cell cells were seeded at a density of 7.5 × 10 3 /well, 5 × 10 4 /well, and 2 × 10 4 /well, respectively, in quadruplicate wells of a 12-well plate. Cell numbers were counted on days 2, 4, and 6 after seeding.
Colony formation assay
The miRNA-transduced cells were suspended in culture medium containing 0.4%
(wt/vol) agar (SeaPlaque GTG agarose; Lonza, Tokyo, Japan) and layered on top of culture medium containing 0.53% (wt/vol) agar at a density of 1.2 × 10 4 /well in triplicate wells of a six-well plate. Colonies were allowed to form for 14 days and were then stained with MTT dye. Colonies ≥200 μm in diameter were counted using ImageJ software (http://imagej.nih.gov/ij/).
Cell cycle analysis
The siRNA-transfected A549 and H441 cells and lentivirally transduced BEAS-2B cells were seeded at a density of 4 × 10 5 /well into triplicate wells of a six-well plate.
After 48 h, cells were harvested, washed with phosphate-buffered saline (PBS), and fixed with 70% ethanol. After treatment with RNaseA (Sigma-Aldrich), the cells were stained with propidium iodide (Sigma-Aldrich), and flow cytometry analysis was performed.
Apoptosis assay
The siRNA-transfected A549 and H441 cells were seeded at a density of 4 × 10 5 /well into a six-well plate. After overnight incubation, the cells were serum-starved for 24 h, (GSE39904) (35) . Gene ontology (GO) analysis and gene set enrichment analysis (GSEA) were performed as described previously (36, 37) .
Quantitative reverse transcription-PCR (RT-PCR)
Total RNA was extracted from the cells, and first-strand cDNA was synthesized using SuperScript III Reverse Transcriptase (Invitrogen). Quantitative RT-PCR analysis was performed using the Mx-3000P qPCR System (Stratagene, La Jolla, CA, USA) and QuantiTect SYBR Green PCR (Qiagen) according to the manufacturer's protocol. The expression levels were normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The PCR primers used are listed in Supplementary Table S2 .
ELISA
The siRNA-transfected A549 cells were seeded at a density of 1.5 × 10 5 /well into triplicate wells of a six-well plate. After 48 h, the culture medium was changed to serum-free medium. The cells were cultured for another 48 h, and the culture supernatant was collected. Lentivirally transduced BEAS-2B cells were seeded at a density of 1.5 × 10 5 /well in epidermal growth factor (EGF)-deprived medium, and the culture medium was collected after 48 h. The concentration of amphiregulin was determined using the Human Amphiregulin DuoSet (R&D Systems) following the manufacturer's protocol.
Statistical analysis
The correlations between TAZ expression levels and clinicopathological parameters or between TAZ and amphiregulin protein expression levels were analyzed by the χ 2 test.
Kaplan-Meier plots were used to visualize the difference in survival between the two groups. The statistical significance of the differences was determined by the log-rank test. Furthermore, univariate and multivariate Cox models were fitted with inclusion of established prognostic parameters: age, patient performance status, and stage at diagnosis. Spearman's rho was used to quantify the correlation between gene-gene and gene-protein expression levels. The differences between the experimental groups were examined for statistical significance using Student's t-test, Wilcoxon's rank-sum test, or analysis of variance (ANOVA) with Tukey's post hoc test. The analyses were conducted using JMP, version 9.0.3 (SAS Institute Inc., Cary, NC, USA). P < 0.05 was considered significant. All data are expressed as means ± SEM.
RESULTS
TAZ gene expression and its clinical correlations in human NSCLC
Our study population was based on a clinically well-characterized lung cancer cohort comprising 196 patients (Uppsala cohort). The tumor tissues were annotated previously for KRAS and EGFR mutations, whole genome gene copy number changes, and gene expression profiles (22, 38) . Three probe sets (202132_at, 202133_at, and 202134_s_at) with strong correlation (rho = 0.52-0.83) represent TAZ on the Affymetrix U133 Plus 2.0 array (GSE37745). Higher transcript levels of TAZ correlated with squamous cell carcinoma histology (P = 0.002) and younger age (P = 0.011, Supplementary Table S3) .
TAZ gene expression levels were lower in tumor samples harboring EGFR mutations than in EGFR/KRAS mutation-negative samples (P = 0.046, Supplementary Fig. S1A ).
Research. No correlations between TAZ mRNA expression levels and the other evaluated parameters (sex, smoking status, stage, and performance status) were found (Supplementary Table S3 ). The correlation between gene expression profiles and gene copy number levels, determined from the Affymetrix 250K SNP arrays, indicated that the mRNA levels can be explained in part by differences in the gene copy number of the corresponding TAZ gene locus (P < 0.001, To substantiate the potential prognostic impact of the probe set 202134_s_at, a meta-analysis was performed. The analysis, which included nine independent, publicly available lung cancer data sets, confirmed the association of higher TAZ mRNA levels with shorter survival (Fig. 1B , HR = 1.21; CI = 1.10-1.33; P < 0.001). This prognostic impact was pronounced in the adenocarcinoma subgroup (Fig. 1C , HR = 1.33; CI = 1.16-1.52; P < 0.001) but could not be demonstrated when the squamous cell carcinoma subgroup was analyzed alone (HR = 1.05; CI = 0.90-1.22; P = 0.568).
TAZ protein levels in human NSCLC
To transfer our findings from mRNA to in situ protein levels, immunohistochemistry Fig. S2A ). Lung cancer tissues revealed variable staining patterns, ranging from strongly positive ( Fig. 2A) to completely negative (Fig. 2B ).
Immunohistochemical staining scores correlated well with gene expression levels in the same cancer sample, indicating the reliability of the antibody ( Supplementary Fig.   S2B ).
For statistical analysis, the scores were dichotomized into low versus high TAZ protein levels in the NSCLC cases. Correlation with clinical parameters revealed that high levels were more common in squamous cell carcinoma (Supplementary Table S4 ).
No correlations were observed between TAZ protein levels and other clinical parameters, including EGFR and KRAS mutation status ( Supplementary Fig. S1B ). In correspondence with the gene expression results, high TAZ protein levels were associated with shorter survival in the univariate analysis (Table 1 , left: HR = 1.40, CI = 1.06-1.82, P = 0.019), as illustrated by the Kaplan-Meier analysis (Fig. 2C) . When we evaluated the adenocarcinoma and squamous cell carcinoma subgroups separately, a trend was observed in the univariate analysis (P = 0.160 and P = 0.087, respectively).
The prognostic relevance in the whole cohort was retained in the multivariate analysis (Table 1, 
explained, at least in part, by gene copy number changes. These results indicated differential expression of TAZ in NSCLC and suggested that high TAZ expression at the genomic, mRNA, and protein levels might define a clinical subset of NSCLC patients.
In vitro analysis of TAZ in lung cancer cell lines and bronchial epithelial cells
To generate TAZ loss-of-function models, A549 and H441 human lung adenocarcinoma cells, which express endogenous TAZ, were used for the silencing experiments. Cells were transiently transfected with NTC or TAZ siRNA. A549 cells were also lentivirally transduced with artificial miRNAs against TAZ for colony formation assay and tumorigenicity assay. To establish TAZ gain-of-function models, immortalized human bronchial epithelial cells (BEAS-2B) were lentivirally transduced with control GFP or TAZ. Knockdown or overexpression of TAZ was confirmed by immunoblotting ( Fig. 3A and Supplementary Fig. S3A ). The cells did not show morphological changes after siRNA transfection or lentiviral transduction.
We investigated the effect of TAZ on cell proliferation. TAZ knockdown in A549 and H441 cells inhibited cell proliferation (Fig. 3B) , while TAZ overexpression in BEAS-2B cells enhanced cell proliferation slightly (Fig. 3C) . Soft agar colony formation assays showed that A549 cells with miRNA-mediated TAZ knockdown exhibited a reduction in anchorage-independent growth on soft agar (Supplementary Fig.   S3B ). 
the G0/G1 fraction was increased by TAZ knockdown in A549 cells (Fig. 3D) , while G1/S transition was promoted by TAZ overexpression in BEAS-2B cells (Fig. 3E) .
To investigate the involvement of TAZ in apoptosis, A549 and H441 TAZ-knockdown cells were serum-starved, and apoptotic cells were detected by annexin V staining. We found a significant increase in apoptosis induced by serum deprivation in A549 and H441 cells after TAZ knockdown (Supplementary Fig. S3C ).
These results supported that the TAZ oncogene promotes lung cancer proliferation and survival.
Tumorigenic impact of TAZ in a mouse model
To assess the potential tumorigenicity of TAZ in vivo, a xenograft mouse model was generated by injecting nude mice with miRNA-transduced A549 cells or TAZ-transduced BEAS-2B cells. All the mice injected with miRNA-transduced A549 cells developed tumors, and TAZ knockdown reduced tumor growth (Fig. 3F) . On the other hand, during the observation period, 5 of 10 mice injected with TAZ-transduced BEAS-2B cells developed tumors, while only one mouse demonstrated minimal tumor growth after 6 months in the control group ( Supplementary Fig. S3D and E). Tumor samples showed similar cell morphology (Supplementary Fig. S3F ). These results indicated the potential role of TAZ in tumorigenesis of bronchial epithelial cells.
Gene expression profiling in TAZ knockdown lung cancer cells
To identify the downstream targets of TAZ in lung cancer cells, we performed microarray-based expression profiling analysis in A549 cells after TAZ knockdown. Table   S5 ). To characterize these 259 genes, we performed GO analysis and found that a large portion of the TAZ-regulated genes is associated with cell cycle regulation (Fig. 4B) .
The in vitro findings were recapitulated in human NSCLC tissues of the Uppsala cohort using GSEA. TAZ-regulated genes were clearly enriched in NSCLC with high TAZ expression (Fig. 4C) . These genes were also enriched in NSCLC tissues of patients with poor prognosis (Fig. 4D ), suggesting that TAZ target genes might be responsible for the aggressive phenotype of NSCLC. Table S5 ). Since the EGFR family and its ligands play an important role in lung cancer, these findings prompted us to validate the microarray data and to explore the TAZ-mediated regulation of the three ErbB ligands in detail.
TAZ regulates expression of ErbB ligands in lung epithelial cells
The gene expression differences determined by microarray analysis of the ErbB ligands in A549 cells were confirmed by quantitative RT-PCR (Fig. 5A ). We also found that they were upregulated in TAZ-overexpressing BEAS-2B cells. ELISA assays showed that TAZ knockdown led to decreased amphiregulin protein levels in the culture medium of A549 cells (Fig. 5B ). In line with this, TAZ overexpression increased amphiregulin protein levels in the supernatant of cultured BEAS-2B cells. We found that the promoter regions of the three ErbB ligands contain putative recognition motifs for TEAD, a major transcription factor that binds TAZ ( Supplementary Fig. S4B and C).
Correlation between TAZ and ErbB ligand expression in NSCLC
We next investigated whether there is a correlation between TAZ and ErbB ligand expression using publicly available microarray data sets. There were positive correlations in the NSCLC cell lines according to two data sets, GSE4127 (39) and GSE4824 (40), except for neuregulin 1 in GSE4127, in which only a trend towards a positive correlation was observed (Fig. 5C ). The correlation between TAZ and amphiregulin expression was also analyzed in human cancer tissues using Furthermore, a positive correlation between TAZ and amphiregulin protein levels was found (P < 0.001, Fig. 5D ).
To evaluate whether the EGFR pathway was activated in NSCLC with high TAZ expression, we again used GSEA. An EGFR signaling-related gene set from a previous study (41) was enriched in NSCLC with high TAZ expression in the Uppsala cohort (P = 0.004, Fig. 5E ). Three other EGFR signaling-related gene sets also showed positive correlations with high TAZ expression, but they did not reach statistical significance ( Supplementary Fig. S6A ) (42, 43) . Immunoblot analysis showed that TAZ overexpression increased EGFR phosphorylation in BEAS-2B cells, although we failed to observe decreased EGFR phosphorylation after siRNA-mediated TAZ knockdown ( Supplementary Fig. S6B ). Altogether, these findings suggested that TAZ activates the EGFR signaling pathway through the induction of EGFR ligands.
Correlation between TAZ expression and sensitivity to EGFR inhibitors
To investigate whether EGFR inhibition is a reasonable treatment strategy for NSCLC with high TAZ expression, drug sensitivity data and gene expression profiles in NSCLC cells were obtained from the Cancer Cell Line Encyclopedia (CCLE) database (44) . We found that TAZ expression tended to be higher in NSCLC cell lines with high sensitivity to two EGFR tyrosine kinase inhibitors (EGFR-TKIs), while there were no apparent associations between TAZ expression and sensitivity to other anti-cancer drugs (Supplementary Fig. S7A ). In addition, 139 genes that define gefitinib sensitivity (45) Research. were enriched in NSCLC with high TAZ expression (Supplementary Fig. S7B ). Thus, the in silico analysis indicated a rational strategy for EGFR inhibition in TAZ-positive NSCLC.
DISCUSSION
Using an integrated approach, we characterized TAZ expression at the genomic, mRNA, and protein levels in a large, well-annotated NSCLC patient cohort to combine comprehensive molecular data with clinical parameters and to identify TAZ as an independent prognostic marker. Consistent with the in situ findings in human lung cancer tissue, TAZ promoted lung cancer/epithelial cell proliferation in vitro and tumor development in an in vivo mouse model. Finally, based on multiple experimental lines, tumorigenic effects might be regulated through EGFR signaling.
The association of higher TAZ expression with shorter survival in lung cancer patients was described previously in one study (20) . However, there were certain differences of interest. First, the staining pattern of the antibody used in our study clearly indicated TAZ expression in normal alveolar and bronchial epithelial cells as well as in stromal cells. TAZ protein expression in non-neoplastic lung tissue was not described in the previous report. Secondly, as opposed to the previous study, TAZ expression levels were in general higher in squamous cell carcinoma in our study, which was also supported by analyses of all other microarray data sets (data not shown).
This discrepancy might be caused by differences in the clinicopathological features of the study cohorts and/or the methods used for immunohistochemistry, including the use of different antibodies. 
We found a clinical subset of NSCLC patients with high TAZ expression at the genomic, mRNA, and protein levels in the Uppsala cohort. The previous studies showed that high level of TAZ gene amplification analyzed by GISTIC algorithm was observed in 35 of 178 squamous cell carcinomas (19.7%) (46) and one of 182 adenocarcinomas (0.5%) (47) . This is consistent with the finding that TAZ expression levels were higher in squamous cell carcinoma in our study. They also showed that TAZ mutation was found in only one case (0.6%) of squamous cell carcinomas, and two cases (1.1%) of adenocarcinomas, suggesting TAZ activation may not be generally caused by genetic mutations.
We showed that miRNA-mediated TAZ knockdown in A549 cells exhibited tumor growth reduction in a xenograft model, which was consistent with the previous study (19) . Furthermore, we found that TAZ-transduced BEAS-2B cells showed a higher frequency of tumor formation in nude mice. Because lentiviral transduction of BEAS-2B cells may itself induce tumorigenesis (48), the results in this model should be interpreted with caution and will require further investigation.
To further explore which signaling pathways TAZ regulates, we performed a comparative gene expression analysis and identified amphiregulin, epiregulin, and neuregulin 1 as candidate genes. We demonstrated that TAZ induces amphiregulin secretion from lung epithelial cells. Our results were consistent with a previous report that TAZ increased amphiregulin production in mammary epithelial cells (49) .
Epiregulin and neuregulin 1 were also among the potential targets found in the microarray screening of A549 cells, as well as MCF10A and SW480 cells, with TAZ knockdown (13, 35) . Importantly, their promoter regions were likely to harbor TEAD-binding sites, suggesting direct regulatory interactions. 
EGFR-TKIs are now widely accepted as effective therapeutic strategies for EGFR mutation-positive NSCLC patients. However, some EGFR mutation-negative patients also benefit from EGFR-TKI treatment (50) . Indeed, a previous study linked increased expression of the EGFR ligand amphiregulin to improved clinical outcomes in EGFR mutation-negative patients treated with EGFR-TKI (51) . TAZ expression may help to identify those patients who would benefit from treatment with EGFR-TKIs. We report here supportive findings using data from the CCLE database. However, it should be stressed that other strategies have been suggested to inhibit oncogenic TAZ activation, including direct targeting of TAZ, Rho and Rock inhibitors, and upstream WNT inhibition (6).
Indeed, our integrative microarray analysis indicated several other mechanisms of TAZ-induced tumorigenesis. TAZ may facilitate cancer progression through activation of tumor-promoting genes, such as CTGF, Cyr61, and cyclins (CCND1 and CCND3).
Further studies are clearly warranted to identify the TAZ-dependent regulatory network in cancer.
In summary, our study confirms the tumorigenic impact and clinical significance of TAZ expression in NSCLC and sheds light on the regulatory mechanisms and the potential for TAZ as a therapeutic target in the era of personalized medicine. A and B, the tissue microarray, consisting of 345 evaluable NSCLC cases, was stained with a polyclonal antibody against TAZ, and representative immunostaining images are presented for high (A) and low TAZ expression (B). C, the staining scores (0-9 as a product of the staining intensity and the proportion of stained tumor cells) were dichotomized (0-6 vs. 9) and used for stratification in the Kaplan-Meier analysis. P value was obtained using a log-rank test. 
